Astrocytic sEH-EET signaling regulates microglial lysosomal function and suppresses the STING-Type I interferon pathway in Alzheimer's disease

The brain is not a static organ; it is a living landscape constantly patrolled by its own immune system. In this system, specialized cells called microglia act as the first responders, scanning for debris, clearing away waste, and sounding the alarm when trouble arises. When this system malfunctions, as it does in Alzheimer's disease, the cleanup crew can become overwhelmed or confused, leading to a state of chronic inflammation that damages healthy brain cells. A key part of this breakdown involves a signaling pathway known as STING, which, when stuck in the "on" position, triggers a flood of inflammatory messages that harm the brain. Another critical player is the lysosome, a tiny compartment inside cells that functions like a recycling center, breaking down waste and also serving as the place where inflammatory signals are turned off. For the brain to stay healthy, these recycling centers must work efficiently to clear both physical trash and dangerous chemical signals.

Scientists have long known that a specific enzyme called soluble epoxide hydrolase, or sEH, is elevated in the brains of people with Alzheimer's disease. This enzyme breaks down beneficial fatty acids known as EETs, which naturally calm inflammation and protect nerve cells. While researchers suspected that stopping this enzyme might help, the exact chain of events connecting sEH to the brain's immune response remained a mystery. A new study by researchers at Baylor College of Medicine and the National Institutes of Health has now mapped out this connection, revealing a precise mechanism by which the brain's support cells control the immune system's most destructive pathways.

The team began by looking at the brains of mice engineered to develop Alzheimer's-like plaques. They compared mice with normal sEH levels to mice that had been genetically modified to lack the enzyme entirely. Using a high-resolution technique that reads the genetic activity of thousands of individual brain cells at once, they discovered that removing sEH changed the behavior of the brain's immune cells. In the mice without sEH, the microglia were less likely to enter a hyper-aggressive state driven by interferon, a type of inflammatory signal that damages neurons. Instead, these cells remained closer to a calm, homeostatic state. The researchers found that the absence of sEH led to higher levels of the protective EETs, which in turn reduced the activation of the STING pathway, effectively silencing the inflammatory alarm.

To understand how this happened, the scientists turned to cell cultures in the lab. They treated mouse microglia with synthetic EETs and then stimulated them to activate the STING pathway. They observed that the EETs prevented the STING protein from accumulating and triggering inflammation. Crucially, they found that this protective effect depended entirely on the lysosome. When the researchers blocked the lysosome's ability to acidify and break down materials, the EETs could no longer stop the inflammation. This revealed that EETs work by boosting the lysosome's efficiency, allowing it to degrade the activated STING protein and terminate the inflammatory signal. Without a functioning lysosome, the signal remains stuck, but with EETs enhancing the process, the signal is cleared away.

The study also showed that EETs improved the microglia's ability to perform their primary job: eating and clearing away amyloid-beta, the sticky protein that forms the hallmark plaques of Alzheimer's disease. Cells treated with EETs swallowed more of these protein clumps and broke them down faster. This suggested a dual benefit: the same mechanism that calms the immune system also helps the brain physically clean itself.

A major question remained: which cell type in the brain is responsible for producing the signals that regulate this process? sEH is found in several cell types, including the cells that line blood vessels and the star-shaped support cells called astrocytes. To solve this, the researchers created mice where sEH was removed only from astrocytes, and other mice where it was removed only from blood vessel cells. They discovered that removing sEH from astrocytes alone was enough to reduce amyloid plaques and calm the microglia, just as removing it from the whole body did. In contrast, removing sEH from the blood vessel cells had no significant effect on the brain's pathology. This pinpointed astrocytes as the primary source of the regulatory signals that keep microglia in check.

The findings suggest a clear line of communication between different brain cells. Astrocytes, by controlling the levels of sEH, determine how much protective EET is available to the microglia. When sEH is high, EET levels drop, the lysosomes in microglia become less efficient, and the STING pathway stays active, driving inflammation and preventing the clearance of toxic proteins. When sEH is low, EET levels rise, the lysosomes work better, the inflammatory signal is turned off, and the microglia can effectively clean up the brain. This study does not offer an immediate cure, but it provides a detailed map of a specific biological pathway that links cellular metabolism to immune regulation. By identifying astrocytes as the key regulators of this process and lysosomes as the critical switch, the research highlights a potential target for future therapies aimed at restoring the brain's natural ability to manage inflammation and clear waste.